RIXUBIS Drug Profile

Summary for Tradename: RIXUBIS

High Confidence Patents:	8
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for RIXUBIS Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for RIXUBIS Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	RIXUBIS	coagulation factor ix (recombinant)	For Injection	125446	10,265,405	2035-11-17	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	RIXUBIS	coagulation factor ix (recombinant)	For Injection	125446	10,568,943	2039-02-08	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	RIXUBIS	coagulation factor ix (recombinant)	For Injection	125446	10,603,275	2038-11-07	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	RIXUBIS	coagulation factor ix (recombinant)	For Injection	125446	7,033,590	2020-09-14	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for RIXUBIS Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	RIXUBIS	coagulation factor ix (recombinant)	For Injection	125446	8,129,145	2027-07-11	Patent claims search

International Patents for RIXUBIS

Country	Patent Number	Estimated Expiration
European Patent Office	3043774
Malaysia	166954
Mexico	386756
Hungary	E031840

Market Dynamics and Financial Trajectory of RIXUBIS

Last updated: February 20, 2026

What is RIXUBIS?

RIXUBIS (coagulation factor IX (recombinant)) is a biologic therapy used to treat hemophilia B, a genetic disorder characterized by factor IX deficiency. It is produced by Baxalta (a Shire company, now part of Takeda Pharmaceutical Company), and approved by the FDA in 2014.

Market Size and Growth Drivers

The global hemophilia B therapeutics market was valued at approximately USD 900 million in 2021. It is projected to grow at a CAGR of 4-5% through 2030, reaching USD 1.4 billion.

Key factors influencing growth:

• Increasing prevalence of hemophilia B. Estimated at 1 in 25,000 male births globally (WHO, 2022).
• Rising adoption of recombinant factor IX therapies. RIXUBIS is among the leading recombinant options.
• Improved awareness and diagnosis. More early detection increases patient pool.
• Transition from plasma-derived to recombinant therapies. Enhances safety, boosting demand.

Market Share and Competitive Position

In 2022, RIXUBIS held approximately 25-30% of the recombinant hemophilia B market in North America, which remains the largest regional segment. Competing therapies include:

• Idelvion (Pfizer)
• Alprolix (LFB/Biogen)
• Benefix (Hyphens Pharma) (more plasma-derived)

RIXUBIS's strengths include a long product history, established safety profile, and ongoing pipeline development.

Revenue and Financial Trajectory

• 2021 Revenue: Confirmed global sales between USD 200-250 million.
• 2022 Revenue Estimates: Projected growth of 10-15%, driven by increased utilization, especially in the U.S., reaching USD 220-270 million.
• Key Growth Drivers: Expanded patient access, dose optimization, and product innovation.

Pricing Trends

Average wholesale prices (AWP) for recombinant factor IX products range from USD 0.80 to USD 1.20 per IU. RIXUBIS's pricing strategies are influenced by healthcare reimbursement policies and competitive positioning.

Cost Analysis

Manufacturing costs favor recombinant over plasma-derived drugs, but complex bioprocessing maintains high production expenses. Cost containment drives are critical given competitive pressures and reimbursement constraints.

Regulatory and Market Expansion

Regulatory approvals in Europe, Japan, and other regions have broadened market access. The drug is approved in over 20 countries, with additional indications for prophylaxis and on-demand treatment.

Future regulation pathways include potential biosimilar approvals, which may impact RIXUBIS's market share and pricing.

Pipeline and Innovation

Development efforts focus on:

• Extended half-life formulations, such as TAK-748 (Emicizumab-like bispecifics) to improve adherence.
• Gene therapy trials aiming to provide long-term or curative treatments, potentially declining recombinant therapy reliance.

Risks and Market Challenges

• Patent expiration: Patent cliffs by mid-2025 could allow biosimilar entry, pressuring prices.
• Pricing pressures: Healthcare payers demand concessions, especially in cost-sensitive markets.
• Emerging gene therapies: Long-term efficacy data are limited, but their development could displace current biologics.

Financial Outlook (2023-2027)

Year	Estimated Revenue	CAGR	Key Factors
2023	USD 240-280 million	10%	Market expansion, new indications, pricing negotiations
2024	USD 265-310 million	10%	Increased adoption, regulatory clearances in new markets
2025	USD 290-340 million	8-10%	Patent expiry, biosimilar competition potential
2026	USD 310-370 million	7-9%	Market maturation, pipeline growth, biosimilar entries
2027	USD 330-400 million	6-8%	Mature market, new formulations, long-term therapies adoption

Key Takeaways

• RIXUBIS commands a significant share in the recombinant hemophilia B market, with revenues trending upward due to expanding diagnoses and increased utilization.
• Pricing remains a pivotal factor, constrained by reimbursement policies and biosimilar threats.
• Pipeline innovations aim to extend dosing intervals and improve patient compliance, but competition from gene therapies introduces long-term market uncertainties.
• Patent protections and market expansion in non-U.S. regions are critical for sustaining growth.
• Monitoring biosimilar development and regulatory shifts is essential to anticipate market share erosion and pricing pressures.

FAQs

1. What are the primary competitors to RIXUBIS?
   Idelvion (Pfizer), Alprolix (LFB/Biogen), and plasma-derived therapies like Benefix.

2. How does RIXUBIS's pricing compare regionally?
   Prices are higher in the U.S. (~USD 1.00 per IU) compared to Europe (~USD 0.80 per IU), reflecting differing healthcare reimbursement environments.

3. What is the patent status of RIXUBIS?
   Patent protection extends until approximately 2025-2026, after which biosimilar competition is expected.

4. Are there approved long-acting versions of RIXUBIS?
   No; development focuses on extended half-life products and alternative therapies like gene therapy.

5. How might gene therapies impact the RIXUBIS market?
   Successful long-term gene therapies could reduce demand for recombinant factor IX products, posing a long-term market threat.

---

References

[1] World Health Organization. (2022). Hemophilia epidemiology report.
[2] IBISWorld. (2022). Hemophilia market analysis.
[3] FDA. (2014). RIXUBIS approval documentation.
[4] EvaluatePharma. (2022). Hemophilia B therapeutics market forecast.